MS‐275 is a class I HDAC selective inhibitor that can inhibit the cellular function of HDAC1/2/3 to prevent malignant cancer proliferation.[53] As studies have proven the efficacy of HDAC3 in osimertinib‐resistant lung cancer cells, we chose this drug to investigate its synergistic effect with EGFR degraders. Here, HDAC3 is linked to lung carcinoma.